Hormonal
Semaglutide 2.4 mg administered subcutaneously once weekly reduces major adverse cardiovascular events (MACE) in patients with established cardiovascular disease and overweight or obesity, independent of diabetes status.
If you have established heart disease and are overweight or obese, but do not have diabetes, semaglutide 2.4 mg once weekly is a treatment option being tested to reduce your risk of heart attack, stroke, or cardiovascular death. It is taken as a weekly injection, started at a low dose to minimize stomach side effects, and used alongside standard heart health care. This approach targets obesity as a direct cause of cardiovascular risk, independent of blood sugar levels.
SELECT is a randomized, double-blind, parallel-group trial testing if semaglutide 2.4 mg subcutaneously once weekly is superior to placebo when added to standard of care for preventing major adverse cardiovascular events in patients with established CVD and overweight or obesity but without diabetes.
Why this rating
This is a large-scale, randomized, double-blind, placebo-controlled Phase 3 clinical trial (SELECT) with ~17,500 participants, representing the highest level of clinical evidence.
Source
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design
Donna H. Ryan et al. · American Heart Journal · 2020
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →